Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women

Inclusion Criteria: * Postmenopausal women, age: ≥ 60 years to ≤ 85 years at randomization * Degenerative primary hip osteoarthritis as the indication of hip replacement * Signed informed consent Exclusion Criteria: * Presence of severe osteoporosis (T-score less than -4.0 and a previous fracture) * Presence of Dorr C-type geometric change of the proximal femur * Evidence of secondary osteoporosis * Clinical or laboratory evidence of hepatic disease * Laboratory evidence of hypocalcaemia * Vitamin D deficiency (serum 25-OH(D) \< 12 ng/mL) * Disorders of parathyroid function * Uncontrolled hyperthyroidism or hypothyroidism * History of malignancy, radiotherapy or chemotherapy for malignancy (except basal cell carcinoma of the skin) within the last 5 years * History of osteonecrosis of the jaw * History of recent tooth extraction or other dental surgery and/or invasive dental work planned in the next 2 years * Severe asthma or chronic obstructive pulmonary disease * History of solid organ or bone marrow transplant * Use within 12 months of drugs that affect bone metabolism such as ant-osteoporotic agents (including SERMS), estrogens, testosterone, and anti-epileptics: * Cumulative dose of 500 mg prednisone or equivalent within the last 6 months * Ever use of oral or iv bisphosphonates * Ever use of strontium ranelate or fluoride * Use of the following medications: * chronic systemic ketoconazole * androgens * cinacalcet * aluminum * lithium * protease inhibitors * gonadotropin-releasing hormone agonists * Rheumatoid arthritis or any other inflammatory arthritis * History of skeletal disorder, such as Paget's disease or osteomalacia * Alcohol abuse * General * Mental, neurological or other conditions that may affect the ability to perform functional or clinical assessments required by the protocol * Subjects with known sensitivity or intolerance to any of the products to be administered (calcium and D-vitamin supplements, denosumab) * Subject will not be available for protocol-required study visits, to the best of the subject's and investigator's knowledge * Any other condition that, in the judgement of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures